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Introduction
The utility of the mouse in aiding our understanding of disease is clear; the ability to manipulate its genome, a short breeding cycle, defined genetic backgrounds, and the array of phenotypic interrogations available for the mammalian physiology have all helped elucidate the pathogenesis of disease. Whilst ageing is a risk factor for a range of diseases (Niccoli and Partridge, 2012) and there are many efforts to understand the effect of ageing through the modulation of ageing itself (Fontana et al., 2010; Guarente, 2014) it is also clear many diseases have a significant genetic component. This genetic susceptibility may be exacerbated in the context of an ageing physiology, thereby resulting in the observed increased disease risk with age. Thus, the study of individual disease pathways through specific mouse models could aid our understanding of not only disease but also the increased risk associated with ageing. Studies in young mice are often fruitful, but to understand disease, model it accurately, and subsequently test interventions it is only logical that if one is studying a chronic or age-related disease the best models will be chronic or have an ageing component. The disease burden faced by the aged is wide-ranging and varies from individual to individual but there are diseases that are common among aged patients. It is therefore a challenge in many disease areas to include the role of ageing, which may add additional complications or comorbidities that compound the underlying condition (Fabbri et al., 2015) . Here we highlight a subset of relevant illnesses and how mice, young, old, and indeed with accelerated ageing, have been used to study them. In this review we highlight the potential impacts of ageing on disease susceptibility in a range of disease areas to emphasise the relevance of current models, and make suggestions for refinements and new developments.
Acute trauma and sepsis
Although traumatic injuries are not the main cause of death in people aged ≥60 years, traumas like falls or motor vehicle collisions are associated with an increased mortality risk in elderly patients (Sampalis et al., 2009; Schoeneberg et al., 2014) . Often, the trauma itself is not the actual killer; most frequently, the main cause of the ensuing morbidity/mortality in those patients are secondary infections rapidly progressing to sepsis and/or multiple organ dysfunction syndrome (MODS) (Angus, 2001; Frohlich et al., 2014) . Susceptibility and mortality from systemic infections increase with patient's age, and sepsis is among the leading causes of death in ageing patients worldwide (Angus, 2001; Wafaisade et al., 2011) . To study the above mentioned critical care conditions, the availability of effective age modeling approaches is essential.
Regardless whether trauma or infection occurs, similar immuno-inflammatory reactions are triggered via either DAMPS (danger associated molecular patterns) or PAMPS (pathogen associated molecular patterns) (Lord et al., 2014; Boomer et al., 2014) . With advanced age, the host's capability to mount an adequate immune response against inflammatory stimuli declines. This phenomenon is apparent in humans and laboratory animals, including mice (Frasca and Blomberg, 2015) . For example, while the number of B-cells and naïve T-lymphocytes decreases, T 2 -helper cells (producing the anti-inflammatory interleukins (IL) 4 and 10) accumulate (Linton et al., 1996; Miller, 1996; Weksler et al., 2002) . Simultaneously, ageing is associated with a persistent low-grade increase of various pro-inflammatory and acute phase proteins, many of which are independent predictors of mortality/morbidity in patients (Bruunsgaard et al., 2003; Giovannini et al., 2011; Harris, 1999) . All those immunologic changes are part of an age-related decline of physiologic functions termed frailty, which occurs in both humans and mice (Mohler et al., 2014) . Thus, those similar immuno-inflammatory characteristics justify the age-oriented investigative utility of the mouse in critical care conditions. Despite the critical need for such translational studies, preclinical research addressing the mechanisms and impact of age on immuno-inflammatory endpoints is infrequent. The main reason is undoubtedly the financial burden: aged mice must be either purchased (e.g. D 156 for an 18-month old female CD-1 mouse) or "matured" from a young age for 18-24 months. The latter option, although seemingly attractive, poses many underappreciated risks that may eventually surpass the costs of "ready-to-use" mice . Despite those hurdles and recently voiced translational doubts (Seok et al., 2013) , many important and findings stem from mouse studies in critical care (Osuchowski et al., 2014) . In trauma, the majority of existing studies concentrate not on the age itself but rather on the interplay between the age and gender Mees et al., 2007 Mees et al., , 2008 , given that sex hormones influence the immune response and their production is age-dependent. For example, estrogens have demonstrated strong protective effects in sexually mature mice when subjected to sepsis after traumatic insults (Choudhry, 2005) and to burn injuries alone (Kovacs, 2005) . A frequently used model combining laparotomy and hemorrhagic shock Schneider et al., 2007) showed that, similarly to human patients (Livingston et al., 2003) , trauma affects the amount of circulating bone marrow-associated cells in mice (Schneider et al., 2007) . Moreover, the same model demonstrated the (clinically valid) phenomenon of compartmentalisation of immune responses in aged mice, resulting in different responses in distinct tissues. For example an enhanced inflammation in the spleen and inflammatory depression in peripheral blood mononuclear cells (PBMC) can occur conincidently Schneider et al., 2006) .
Recently, more sophisticated polytrauma models combining hemorrhage with bone fractures (Kleber et al., 2015; Wichmann et al., 1998; Wichmann, 1996) , chest trauma (Seitz et al., 2011) or cecotomy (Gentile et al., 2013) have been introduced. Their main strength is that they more closely recapitulate the immunoinflammatory deregulations occurring in trauma patients. These include a reduced cytokine release capacity by splenocytes, peritoneal macrophages (Wichmann et al., 1998; Wichmann, 1996) and PBMCs (Seitz et al., 2011 ) and a loss of major histocompatibility complex class II and CD4+ cells (Gentile et al., 2013) . Similar immuno-inflammatory deficits were shown to be induced in aged mouse burn models (Kovacs et al., 2002 (Kovacs et al., , 2004 Plackett et al., 2003; Nomellini et al., 2008; Plotnikov et al., 2013) . Although traumatic brain injuries (TBI) typically occurs in very young or old humans (Langlois et al., 2006) , experimental mouse studies are primarily performed in young subjects. The only three existing TBI studies comparing young and aged mice demonstrated higher mortality, stronger neurological function deficits and increased inflammatory markers (Kumar et al., 2013; Onyszchuk et al., 2008; Timaru-Kast et al., 2012) in the latter. The most sophisticated, and clinically relevant, approach are so called two-hit models combining these trauma-induced immuno-inflammatory deregulations (e.g. after first-hit hemorrhage, laparotomy, and/or bone fracture insult) and infections/sepsis as a delayed second hit (see below) (Seitz et al., 2011; Gentile et al., 2013; Kovacs et al., 2002 Kovacs et al., , 2004 . The most commonly used trauma models and their application in aged animals are listed in Table 1 .
Sepsis can originate from many sites in the body, most frequently the lungs, abdomen, urogenital tract and iatrogenic sources (e.g. indwelling catheters) (Angus, 2001; Vincent, 2006) and the elderly (and neonates) are most at risk. As our understanding of sepsis pathophysiology and epidemiology has grown, the murine modeling has been gradually evolving in an attempt to match the complex clinical reality but this evolution is too slow regarding the age component. Currently, the live bacteria pneumonias and Schneider et al. (2006) high no -Traumatic brain injury Frank et al. (2009) high yes Plackett et al. (2003) , Nomellini et al. (2008) , Plotnikov et al. (2013) , Cowley et al. (2012) , Kohama et al. (1995) Chest trauma Mawhinney et al. (2011) high no -Burn Li et al. (2009) High/very high yes Wichmann et al. (1998 ),Wichmann (1996 , Seitz et al. (2011 ),Gentile et al. (2013 ) Polytrauma Kleber et al. (2015 , Cowley et al. (2012) very high no Gentile et al. (2014) , Lyons et al. (2009) the cecal ligation and puncture (CLP) peritonitis are considered by many as the most clinically relevant model systems. Both closely mimic the protracted pathophysiologic processes (e.g. concurrent release of pro-and anti-inflammatory mediators, impaired coagulation/fibrinolysis, and organ dysfunction) which typically occur in sepsis patients (Saito et al., 2003; Remick et al., 2000; Esposito and Pennington, 1983; Angus and van der Poll, 2013; Dejager et al., 2011) . Pneumonia is produced via intranasal/tracheal instillation of various pathogens (i.e. Pseudomonas, Klebsiella, Streptococcus pneumonia, Influenza virus) (Starr and Saito, 2014; McConnell et al., 2011; Mares et al., 2010; Shivshankar et al., 2011) , while CLP and colon ascendens stent peritonitis (CASP) induce polymicrobial abdominal peritonitis via leakage of feces from the gut (Hubbard, 2005; Zantl, 1998) . Furthermore, instillation of single or double strains of bacteria into the murine bladder produces urosepsis and revealed the role of bacterial adhesins for retention of bacteria in the urinary tract (Hagberg, 1983a,b) . However, this model has not yet been tested in aged mice. Less relevant peritonitis models include intraperitoneal fecal pellets, fibrin clots containing fecal bacteria (Ahrenholz and Simmons, 1980; Starr et al., 2014; Gentile et al., 2014; Nulsen et al., 1983) , and injection of live/inactivated bacteria (Hyde and McCallum, 1992) . Historically, the administration of a bacterial lipopolysaccharide (LPS) has been the most frequently used experimental setup aiming to produce sepsis-like symptoms. The current consensus is that LPS does not recapitulate the protracted immuno-inflammatory responses of human sepsis (Osuchowski et al., 2014; Remick et al., 2000) . Sepsis models can be successfully used to mimic secondary complications after trauma (i.e. two-hit models) (Drechsler et al., 2012; Nacionales et al., 2015) . Importantly, the clinical relevance of those models critically depends on the severity and mode of action of each hit. For example the more severe the initial trauma, the more likely patients will develop secondary complications (due to dysfunctional/suppressed inflammatory responses). Thus, when combined with a subsequent (two-hit) infectious insult, the relatively lowseverity first trauma hits (e.g. hemorrhage only) appear as an inferior choice. Given that mice possess an innate high resistance to trauma (and inflammation) even severe mouse trauma models cannot recapitulate a full pallet of the most severe responses that occur in patients. It is equally crucial to choose an appropriate sepsis model match (e.g. CLP for abdominal sepsis) and a suitable level of its severity ensuring a clinically-realistic outcome proportion (e.g. approx. 30-40% mortality post-CLP). Finally, different types of sepsis frequently occur simultaneously in immunocompromised (e.g. posttraumatic) patients, thus, combination of different sepsis models is theoretically possible. Yet, such setups appear very burdensome (and ethically problematic) to be tested in aged mice (especially 2-hit scenarios) (Muenzer et al., 2006; Davis et al., 2011) .
Most common available sepsis models and their application in aged animals are listed in Table 2 .
In summary, the similar responses and age-adjusted survival patterns (Turnbull, 2003) further emphasise the utility of welldesigned mouse modeling. The great advantage in mouse modeling of age-related critical care disorders is that it does not require development of new sophisticated modeling platforms solely devoted to this purpose. Thus, the dire demand for age research in trauma/sepsis can be met relatively quickly: it merely requires a thoughtful selection of the most hypothesis-fitting and clinically relevant models (from the myriad of existing variations) and their application in aged mice, typically around 18-24 months of age. The relatively short life time-span of the mouse (compared to larger mammals) allows for multiple repetitions and solid verification of the generated data -a key component of the effective extrapolation to human medicine.
Neuroinflammation
Systemic inflammation occurs with ageing (Frasca and Blomberg, 2015; Franceschi and Campisi, 2014; Ostan et al., 2008) and it is generally agreed inflammatory changes are characteristic of the aged brain and are a prominent feature of most, if not all, neurodegenerative conditions. Neuroinflammation is characterized by increased expression of inflammatory cytokines including interleukin 1 beta (IL-1␤), tumour necrosis factor (TNF)-␣, and interleukin 6 (IL-6), and it has been known for more than two decades that the expression of these cytokines is increased in an age-related manner (Lynch, 2010; Godbout et al., 2005) .
Microglia are the primary source of inflammatory cytokines and numerous studies have reported that the increase in inflammatory cytokines is accompanied by an age-related increase in microglial activation. Consistent with this, microarray analysis has revealed an upregulation of genes associated with inflammation, including genes that are indicative of microglial activation like major histocompatibility complex class II (MHCII) (Lee et al., 2000; Godbout et al., 2005) . Further analyses confirmed the agerelated increase in MHCII and also reported increased expression of other markers of microglial activation including CD68, CD80 and CD86. These changes have also been confirmed by immunohistochemistry and flow cytometry, which demonstrated an age-related increase in CD11b + MHCII + cells in the brain (Lynch, 2010 (Lynch, , 2014 Barrett et al., 2015) . More recently, microarray data obtained from analysing human post-mortem brain tissue identified age-related changes in expression of several immune/inflammation genes, especially in the hippocampus, including IL-1␤, IL-6 and TNF␣ as well as MHCII, especially in the hippocampus, an area that plays an important role in memory. In the choroid plexus, an interface Shivshankar et al. (2011) mono/polybacterial medium no -c) CASP Starr and Saito (2014) polybacterial medium no -d) CLP Dejager et al. (2011 ),Lynch (2010 polybacterial high yes Kumar et al. (2013) , Drechsler et al. (2012) , Lee et al. (2000) , Lynch (2014) 
intratracheal administration of S. pneumoniae).
h Relevance depends on the model design-to-hypothesis match; e.g., low relevance of an inactivated E. coli ip bolus injection to simulate peritonitis, medium relevance of protracted iv infusion of live E. coli to simulate septic shock.
i Simultaneous administration (into the urinary bladder) of maximum 2 bacterial strains; to date, a wide-range polybacterial inoculus (e.g. feces) used in rats (Kovacs et al., 2002) but not mice.
j High relevance does not apply to iv/ip administration of typical lung pathogens (e.g. S. pneumoniae). k Various trauma hits are utilised (e.g. hemorrhage (H), laparotomy (L), bone fracture (BF), acute lung injury (ALI); any order of hits is possible (e.g. H-BF/CLP; CLP/ALI). l Relevance depends on the proper severity match in both hits.
between the brain and the circulation and an important gateway for leukocyte infiltration into the brain (Demeestere et al., 2015) , the anti-inflammatory cytokine IL-4 was elevated, whereas the proinflammatory cytokine, interferon gamma (IFN-␥)was decreased in the aged mouse. This is indicative of a shift toward a proinflammatory state (Baruch et al., 2013) . Additionally, a chronic ageing-induced type I interferon signature was observed at the brain's choroid plexus, which negatively influences brain function (Baruch et al., 2014) . Microglia share many properties of macrophages, including their ability to respond to numerous stimuli, reflecting the huge array of receptors expressed on their cell surface. In the past few years, it has become clear that microglia, like macrophages, adopt different activation states (at least in vitro) with evidence of polarization to a 'classical' M1 phenotype in response to interferon IFN␥ and an 'alternative' M2 phenotype in response to IL-4 and other anti-inflammatory cytokines. Translation of these phenotypes into the in vivo situation is fraught with difficulties but the evidence suggests that IFN␥ concentration increases with age, in contrast to the decrease in IL-4 (Maher et al., 2006 (Maher et al., , 2005 Nolan, 2005) suggesting an age-related bias towards the inflammatory M1 phenotype. This is also consistent with the proposal that microglia become primed with age, making them more susceptible to subsequent inflammatory stimuli. Thus treatment of aged mice with LPS exerted a more profound effect on sickness behaviour and induced a greater production inflammatory cytokines than in young mice (Godbout et al., 2005) . LPS also induced a greater degree of microglial activation and a more profound depressive behaviour (Godbout et al., 2005) in aged mice (compared with young). Similarly an age-related sensitization to E. Coli has been reported with evidence of exaggerated and persistent behavioral effects (Barrientos, 2006) , which were attributed to IL-1␤ (Frank et al., 2009 ). An increase in responsiveness to amyloid-(A␤), the principal constituent of the plaques in Alzheimer's disease (AD), has also been reported in aged animals whereby central injection of a sub-threshold concentration of A␤ 1−42 in young animals induced a significant effect on IL-1␤ concentration in hippocampus of aged animals (Minogue et al., 2007) .
Interestingly, the evidence indicates that there is an age-related upregulation of genes relating to activation of the inflammasome (Cribbs et al., 2012) ; this cytosolic multiprotein complex is necessary to activate caspase 1 and therefore to process IL-1␤ to its active form. Consistent with this, there is an increase in the expression of cleaved caspase 1 and pannexin 1 in the hippocampus, which is indicative of increased inflammasome activation (Mawhinney et al., 2011) . It is important to note that whereas microglia may be the primary source of inflammatory cytokines, astrocytes are also capable of producing IL-6, IL-1␤ and TNF␣, albeit to a lesser extent than microglia (Li et al., 2009) and there is clear evidence of an increased astrocytic activation with age. Several studies have reported increases in the archetypal marker of astrocytic activation, glial fibrillary acidic protein (GFAP) (Godbout et al., 2005; Lee et al., 2000; Cowley et al., 2012; Kohama et al., 1995; Hayakawa et al., 2007) .
When the brain is not challenged, the primary function of microglia is surveillance; microglial processes sample their microenvironment every few hours (Nimmerjahn et al., 2005) and this surveillance state is somewhat misleadingly called the resting state. Under these conditions microglia are kept in check by ligand-receptor interactions like the interaction between CD200 and CX3CL1 and their respective receptors that are expressed on microglia (Lyons et al., 2007 (Lyons et al., , 2009 but also by a variety of soluble factors (Ransohoff and Perry, 2009) . A decrease in the repressive tone might contribute to microglial activation and it has been shown that both CD200 and CXCL1 are decreased in the hippocampus with age and coupled with evidence of microglial activation. It is also worth noting that IL-4 concentration, albeit low under resting circumstances, is decreased in the hippocampus with age and IL-4-induced phosphorylation of JAK1 (janus kinase 1) and STAT6 (signal transducer and activator of transcription 6, interleukin-4 induced) is similarly decreased (Maher et al., 2005; Nolan, 2005) , whereas IL-1␤-associated signalling through JNK (Jun amino-terminal kinases) is increased (Nolan, 2005) . These signalling pathways were confirmed as being protective as addition of IL-4 to aged animals prevented the age related impairment of long term potentiation (Nolan, 2005) .
The age-related glial activation and increased hippocampal expression of inflammatory cytokines negatively impacts spatial learning and synaptic plasticity. IL-1␤ profoundly affects several behaviours (Goshen and Yirmiya, 2009 ). The first report of its ability to inhibit hippocampal-dependent learning (Oitzl et al., 1993) was confirmed by several other groups (Gibertini et al., 1995; Barrientos et al., 2002) identifying IL-1␤ as key to the inhibitory effect of LPS on hippocampal function. It has also been shown that persistent overexpression of IL-1␤ in the hippocampus results in poor performance in hippocampal-dependent tasks (Hein et al., 2009 ) and is, predictably, associated with microglial activation (Moore et al., 2009) . Chronic upregulation of IL-6 has also been demonstrated to be associated with deficits in learning and microglial activation (Heyser et al., 1997; Sparkman, 2006) although at least one recent study does not entirely concur with this (Donegan et al., 2014) .
In addition to age-related increased hippocampal concentrations of IL-1␤, IL-6 and TNF␣, increases in IFN␥ and IL-18 have also been reported (Griffin, 2006) . These cytokines were shown to exert an inhibitory effect on long-term potentiation (LTP), the most-commonly studied form of synaptic plasticity (the ability of synapses to respond to changes in their activity) (Lynch, 2014; Maher et al., 2006; Curran and O'Connor, 2001; Kelly et al., 2013) . Interestingly, when the age-related microglial activation (which accompanies the increased expression of these cytokines) is decreased by acute administration of minocycline (Griffin, 2006) or IL-4 (Nolan, 2005) , long term potentiation was partially restored. Similarly, longer-term treatments of aged animals with atorvastatin, rosiglitazone or the polyunsaturated fatty acid, eicosapentaenoic acid (EPA), decreased microglial activation and improved the ability of aged animals to sustain synaptic plasticity (Clarke, 2008; Loane, 2009; Lynch et al., 2007) , pointing to a causal relationship between microglial activation and loss of synaptic function. The findings suggest that strategies which reduce neuroinflammation will improve the age-dependent deterioration of the CNS function.
Alzheimer's disease
Age is the most significant risk factor for developing AD (AD), the most common neurodegenerative disorder and the most common cause of dementia. The prevalence of this still untreatable disorder is rising, due to and the increase in the ageing population. It is the estimated that there will be 106 million AD patients by the year 2050 (Brookmeyer et al., 2007) . Consequently, there is an urgent need for the development and characterisation of relevant animal models to facilitate preclinical drug development and translation research through to human clinical trials.
The most widely used animal models of AD are models of a rare form of autosomal dominant familial AD (FAD) which comprises less than 1% of AD cases (see the currently available genetic models at http://www.alzforum.org/research-models). The major advantage of using such models is that genetic causes of FAD are known, while the cause(s) of the most common sporadic AD (SAD) are still unknown and are likely comprise multiple genetic and environmental risk factors. Importantly, although the etiology of sporadic and familial AD is different, both forms of AD develop indistinguishable clinical and neuropathological phenotype. This includes the accumulation of the amyloid plaques, comprised of the aggregated A␤ peptides and hyperphosphorylated protein tau in neurofibrillary tangles (NFTs).
The currently available single transgenic or multiple transgenic FAD mice that express human mutated APP and/or PS1/2 genes do not completely recapitulate AD pathology (reviewed in LaFerla et al. (LaFerla and Green, 2012) ). Although these FAD models show early learning disability and cognitive impairment followed by the accumulation of A␤ and senile plaque formation they do not develop NFTs in their brains (although some show hyperphosphorylation of tau). More importantly, none of the models show profound neuronal loss − a characteristic feature of human AD (reviewed in Gotz (Gotz et al., 2007) ). The amyloid cascade hypothesis predicts that accumulation of A␤ peptides precedes hyperphosphorylation of tau and NFT formation, thus initiating the cascade of events leading to synaptic loss and neurodegeneration. To better model this, transgenic murine models have been developed that express mutated human tau (i.e. MAPT mutation which causes frontotemporal dementia and does not cause AD) together with human mutated APP and/or PS1/2 genes (Lewis et al., 2001; Oddo et al., 2003; Oddo, 2003) . Indeed, these mice show a characteristic senile plaque formation which precedes formation of NFTs and are valuable models to monitor the interrelationship between A␤ and tau accumulation. Over the past two decades, these transgenic murine models of familial AD have significantly contributed to our understanding of the molecular mechanism(s) of the disease, drug development and preclinical testing. However, numerous reported failures of new treatments for AD in clinical trials indicate that the use of genetic models of familial AD does not represent the complete picture of AD in humans. Consequently, there is a pressing need to develop other animal models relevant to the sporadic form (SAD), which represents 99% of AD cases.
Although both forms of AD are highly influenced by ageing, FAD is more aggressive in its progression and manifests at younger age. Understanding the differences between SAD and FAD, and the causes of the build-up in pathologies, may be important in developing models for evaluating interventions against the more common SAD. Furthermore, we should consider incorporating the use of animal models that deal with the issue of extensive neuronal loss (already present in patients with mild-moderate AD and causing cognitive impairment), with the current AD mouse models that primarily model AD pathologies. Such models will enable identification of treatments that target both cognition, due to neuronal loss, and clearance of A␤ and/or tau pathologies, and these are predicted to be more successful than treatments that target the pathology alone. As ageing is the major risk factor of sporadic AD, any models must reflect pathology that develops with age rather than genetic manipulation alone, such as occurs in current FAD models. These models will be important in identification of critical component(s) of the ageing process that drive AD pathology and target them for the treatment/prevention (Table 3) .
Animal models of the apolipoprotein E (apoE), in particular of the apoE4 isoform which is the major genetic risk factor of SAD, are of particular interest both for understanding the role of apoE4 in AD pathogenesis as well as for developing anti-ApoE4 strategies (Holtzman et al., 2000; Michaelson, 2014) . So far these studies have utilised apoE −/− mice (Holtzman et al., 2000; Bales et al., 1997; Bales, 1999) and mice expressing human apoE2, apoE3 or apoE4 (Holtzman et al., 2000; Fagan et al., 2002) . Using knock-in and targeted replacement technologies, humanised ApoE murine models have been developed that express human ApoE2/3/4 genes under the control of the murine ApoE regulatory sequence (see the currently available models at http://www.taconic.com/transgenicmouse-model/). Humanised AD models thus may represent a more relevant model both for familial and sporadic AD as they express the gene of interest under its endogenous promoter. Although humanised murine models would potentially be less acute than the current transgenic models and would need more "ageing" to develop the AD-like pathology, they could identify more relevant drug targets to develop successful therapies against AD. As we evidence novel genetic risk factors of SAD, in addition to apoE4 allele, other risk genes may also be used to better model SAD (reviewed in Medway et al. (Medway and Morgan, 2014) ).
Cardiovascular diseases
Ageing is also one of the main risk factors in the development of cardiovascular diseases (CVD) given that it causes functional alterations in the vasculature as a result of deregulation of the molecular longevity pathways. The ageing heart in mice is comparable with that of humans (Dai and Rabinovitch, 2009 ) but generally require an additional genetic modification for atherosclerosis to occur, as outlined below. Vascular ageing is particularly associated with endothelial dysfunction, arterial stiffening and remodeling, impaired angiogenesis, defective vascular repair, and an increased prevalence of atherosclerosis (Erusalimsky, 2009; Lakatta and Levy, 2003; Novella et al., 2013) . Experimental models of cardiovascular ageing include senescence-accelerated mouse (SAM) model with two substrains: SAM-prone (SAMP) and SAM-resistant (SAMR), each of which exhibits characteristic disorders (Butterfield and Poon, 2005; Takeda et al., 1997) . SAMP8 shows an age-related deterioration of learning and memory at an earlier age, compared with the senescence-accelerated resistant strain (SAMR1) (Butterfield and Poon, 2005) . Vascular studies using these models in male (Novensa, 2010) and female (Novella et al., 2013; Novensa, 2010; Novella, 2010) mice have shown morphological alterations and mechanical and endothelial dysfunction, and they are suitable models for the study of vascular physiological changes during ageing. In addition, studies in mouse models of genes associated with ageing have also been used to understand the connection between ageing and CVD progression. In particular, mice deficient for Sirtuin1 (Sirt1), which would mimic the decreased activity associated with ageing, exhibit enhanced injury in response to ischemia reperfusion studies. Consistently, Sirt1 transgenic mice display reduced injury and cardiac Sirt1-overexpressing mice exhibited delayed cardiomyopathies associated with ageing (summarized in (North and Sinclair, 2012) ).
Atherosclerosis is the most common cause of CVD. Mouse models of this process have been generated by genetic manipulation of lipoprotein metabolism genes which resulted in mice exhibiting hypercholesterolemia and atherosclerosis, providing a useful tool to study lesion progression. Thus, the low-density lipoprotein receptor-deficient (Ldlr-/-) mouse (Ishibashi, 1993 ) is a model of familiar hypercholesterolemia with a plasma lipoprotein profile similar to humans and atheroma lesions induced by a high caloric Western diet. The human apoB response to a high-fat feeding (Purcell-Huynh, 1995) . The most widely used atherosclerotic mouse model is the apolipoprotein E-deficient (ApoE-/-) mice (Plump, 1992; Zhang et al., 1992; Onozuka, 2002; Hartley, 2000) that develops hypercholesterolemia and spontaneous atherosclerosis with a complexity in the lesions resembling those observed in human atherosclerosis (Zaragoza, 2011) . The combination of apoE-deficiency with inactivation of other genes has advanced the knowledge of the underlying pathogenesis of the atherosclerotic process. Whilst this model has been very useful, the rapid onset of atherosclerosis in the mouse model compared to humans (weeks versus years) limits the utility of the model in drug or treatment development. Similarly, the ApoE-/-model does not take into account the effects of ageing on the physiology and the inflammatory response to atherosclerotic lesions; this appears as a serious modeling shortcoming given a strong age-dependent evolution of the immune system toward the pro-inflammatory environment. Despite the significance of CVD in age-related diseases, few mouse models have been developed that integrate physiological ageing element as the basic setting. Available mouse CVD models are summarized in Table 4 .
Several experimental models and methods have been developed to address other cardiac complications.
Heart failure (HF) is a complex syndrome than can be caused by multiple factors, but the consequences of an ageing of the population and the improvement of treatments for ischemic cardiac disease, are aged patients at risk for HF. HF is characterized by a decreased ability of the heart to provide sufficient cardiac output to support the normal functions of the tissues because of impaired filling and/or ejection of blood (Houser et al., 2012) . Research to identify novel targets for HF therapy usually requires preclinical testing in appropriate HF animal models.
HF models were originally developed in rats because of the numerous potential advantages inherent in a small animal model (Patten and Hall-Porter, 2009 ), although the advent of transgenic strategies has made the mouse an invaluable tool to study the pathogenesis of heart failure and to identify novel therapeutic targets. Whereas the rat models have been used extensively to explore the potential for novel pharmacological or molecular agents for the treatment of HF, using animal models can establish causality, confirm proof-of-principal for a particular therapeutic approach, and help people to understand the multifactorial bases for CVD (Yutzey and Robbins, 2007) . Mouse models of HF are usually non genetically altered models subjected to experimental manipulations such as coronary artery ligation, cardiac pressure overload, cardiac volume overload, viral myocarditis, or cardiotoxic cardiomyopathy (Wang et al., 2004) . However, genetically engineered murine models are being developed in which the genes involved are those related to a variety of proteins including cytoskeletal or sarcomeric components, neurohumoral receptors, cell signalling molecules, calcium-regulating proteins, and to extracellular matrix proteins (Wang et al., 2004) .
In mice that have undergone coronary artery ligation the time course of HF is affected not only by the infarcted area but also by the age of animals. Two-month-old C57BL/6N mice tolerate coronary artery occlusion without HF signs, whereas 14-month-old mice develop HF, with only 36% of animals surviving for more than 8 weeks (Gould et al., 2002) . The same limitation occurs with the mice with homozygous null mutations in the high-density lipoprotein receptor SR-BI (scavenger receptor class B, type I) and ApoE, a model of hyperlipidaemia and atherosclerosis which manifests multiple myocardial infarction and HF (Braun, 2002) . These mice survive only a few weeks after birth, limiting their use in HF research.
The senescence-accelerated strain, SAMP8, has also been proposed as a suitable model for the study of cardiac ageing. SAMP8 mice have diastolic dysfunction associated with ageing similar to that observed in humans (Reed et al., 2011) , an increase in ageassociated oxidative damage in RNA and DNA in heart (Gan et al., 2012) , alterations in glucose transport (Kurokawa et al., 1998) , and present pro-inflammatory cytokines associated with the pathogenesis of cardiovascular diseases (Forman et al., 2010 (Forman et al., , 2011 .
Metabolic dysfunction
A variety of metabolic dysfunctions, such as impaired glucose tolerance, insulin resistance (IR), and type 2 diabetes mellitus (T2DM) develop with age. Persistence of diabetes increases the risk of a cluster of chronic life-threatening metabolic diseases such CVD, hepatic steatosis, chronic kidney disease and central nervous system deterioration. The pathogenic mechanisms of age-associated T2DM include impaired insulin secretion from ␤ cells, loss of proper insulin/insulin-like growth factor (IGF1)-signalling mediated by the insulin receptor substrates (IRS) (White, 2014) , and an increase in body weight owing to a reduction in energy expenditure and/or nutrient sensing associated with ageing (Manini, 2010) . A mechanistic insight of carbohydrate metabolism has been obtained from mouse models with genetic manipulations in these pathways (Taniguchi et al., 2006) . Thus, mutant mice for db (Lepr db/db ) or ob (Lep ob/ob ) genes have a deficiency in the leptin hormone sensing system and develop an early-onset obesity, hyperglycemia and IR due to a slower rate of catabolism . Other diabetes-related mouse models are the insulin receptor (Insr)-deficient mice which display severe hyperinsulinemia but die within a few days after birth and the insulin receptor substrate 1 (IRS1)-null mice (a downstream effector of insulin) which develop mild IR. A mouse model that recapitulates most characteristics of T2DM is the Irs2-deficient mouse which is characterized by IR, hyperinsulinemia, hyperglucemia and ␤-cell failure. Irs2-/-females also develop obesity produced by dysregulation of leptin sensitivity . In addition, mouse models with double deficiencies in Insr or Irs2 genes in combination with ApoE-or LDLr-inactivation shed light into the underlying pathogenesis of the relationship between CVD, lipid and carbohydrate metabolism deterioration and insulin-signalling (Baumgartl, 2006; Gonzalez-Navarro, 2007; Han, 2006; Gonzalez-Navarro et al., 2008; Martinez-Hervas, 2014) . These studies have shown that impaired insulin/IGF1-signalling produces life-threatening diseases in mice similar to those in humans. However, reduced insulin/IGF1-signalling can extend life span in lower metazoans and seem to be in conflict with the pathogenic effect in mouse and humans (White, 2014) . Recent studies in brain-specific Irs2-null mice, which resulted in reduced insulin/IGF1 signalling, showed an increased life-span despite glucose and energy homeostasis imbalance and obesity demonstrating the key role of insulin/IGF1-IRS2 pathway in coordinating metabolism and longevity (Taguchi et al., 2007) .
The growth hormone receptor/binding protein (Ghr/bp) KO (GHR-KO) mouse constitutes another relevant model to study regulation of insulin-associated signalling pathways during ageing. GHR-KO mice display decreased GH hormonal signalling and hepatic production of insulin-like growth factor 1 (IGF-1), which leads to a markedly reduced level of circulating IGF-1, reduced growth rate and adult body weight (Zhou, 1997) as well as longer lifespan (Coschigano, 2003) . GHR-KO animals also exhibit decreased plasma insulin level and consequently, higher insulin sensitivity, in part due to decreased proliferation of ␤ cells (Liu, 2004) . Of note, specific suppression of insulin sensitivity in these mice attenuates phenotypic features of slow ageing (Arum, 2014) . Reactive oxygen species (ROS), mitochondrial by-products of oxidative energy metabolism, are considered to be important drivers of the age-related decline; ROS can damage DNA directly or indirectly, resulting in a wide variety of oxidative DNA lesions which accumulate with age in different tissues. In turn, mutations affecting DNA repair further lead to more lesions and premature ageing (Gurkar and Niedernhofer, 2015; Wang et al., 2012) . As such, mouse models bearing genetic mutations of antioxidant enzymes may help in determining its effects on ageing and lifespan. For instance, transgenic mice overexpressing mitochondrial catalase show increased lifespan and reduced oxidative damage (Schriner et al., 2005) . Still, different mouse models have described contradictory and/or inconsistent results, suggesting that mutation of a unique antioxidant enzyme or even that oxidative damage alone may not contribute in full to the ageing phenotype and longevity. Nevertheless, mitochondrial dysfunction appears to possess strong mechanistic links with age-induced metabolic dysfunction, including impaired fatty acid oxidation (FAO), ROS-induced oxidative damage, inflammation and diabetes (Gao et al., 2014; McDonnell et al., 2015) . Indeed, the decline in mitochondrial function during ageing is concomitant with the development of hyperglycemia and hyperinsulinemia (Petersen et al., 2003) , while the prevalence of diabetes is increased in aged individuals. Sirtuin 3 (Sirt3) KO mice present an excellent opportunity to study metabolic changes associated with mitochondrial dysfunction. SIRT3 is a mitochondrial deacetylase that increases mitochondrial energy metabolism by regulating ROS detoxification, ATP generation, mitochondrial dynamics, nutrient oxidation, and the mitochondrial unfolded protein response (UPR) (McDonnell et al., 2015; Brenmoehl and Hoeflich, 2013) . Therefore, SIRT3 plays a key role in regulating fat metabolism and whole-body energy homeostasis; livers of SIRT3 KO mice accumulate lipid and acylcarnitine metabolites and show impaired fatty acid oxidation (FAO) (Hirschey, 2010) . Moreover, when placed on a high-fat diet (HFD), SIRT3 KO mice exhibit accelerated development of several hallmarks of the metabolic syndrome, including weight gain, impaired glucose tolerance, and insulin resistance. In fact, these mice also show hampered insulin secretion in response to glucose, suggesting a diet-induced pancreatic ␤ cell dysfunction and the likelihood of SIRT3 protecting ␤ cells from nutritional stress (Hirschey, 2011) . SAMP1 mice also display several features of dysfunctional energy metabolism. For instance, aged SAMP1 mice display lower oxygen consumption and fat oxidation in parallel with higher plasma glucose, insulin, leptin, and lower adiponectin concentrations, when compared with age-matched SAMR1 mice. Additionally, decreased fatty acid catabolism in the muscles and liver, and increased inflammation and oxidative stress in the adipose tissue, constitute early events in ageing SAMP1 mice (Haramizu et al., 2011) . This characteristic underscores the usefulness of SAMP1 mice in studying factors impacting on the metabolic syndrome during ageing.
The mammalian sodium-coupled citrate transporter NaCT (mINDY), is predominantly expressed in the liver cells and acts as a transporter of Krebs cycle intermediates (Rogers and Rogina, 2015) . Interestingly, mINDY −/− mice are protected from HFD-induced and age-associated insulin resistance, at least in part, by activation of 5 AMP-activated protein kinase (AMPK) and subsequent induction of mitochondrial biogenesis via peroxisome proliferatoractivated receptor-gamma coactivator 1 alpha (PGC-1␣), leading to augmented energy expenditure associated with an increased hepatic lipid oxidation and reduced lipogenesis (Birkenfeld, 2011) . As a result, mINDY −/− mice display reduced adiposity and liver and skeletal muscle lipid accumulation. The above highlights the value of this model in studying age-associated nonalcoholic fatty liver disease (NAFLD), obesity, and type 2 diabetes.
Taurine depletion has been shown to accelerate skeletal muscle senescence leading to early death in mice (Ito et al., 2014a) and administration of taurine affords several beneficial effects in obesity and its comorbidities, including type 2 diabetes. Taurine transporter (TauT) KO (TauTKO) mice exhibit lower body weight and abdominal fat mass compared with WT animals, suggesting that they are resistant to ageing-dependent obesity when maintained on a normal diet. In addition, they also possess more pancreatic ␤ cells and enhanced glucose disposal, despite lower serum insulin levels, implying deterioration in tissue energy metabolism (Ito et al., 2015) . Finally, TauTKO mice also display impaired metabolic adaptation to exercise in the skeletal muscles (Ito et al., 2014b) . As such, this model may help to better understand to which extent the crosstalk between the different metabolic tissues impacts the development of obesity and/or diabetes with ageing.
Interestingly, mouse models of ageing genes have also been used to investigate the tangled relationship between CVD, metabolic derangement and ageing. In some of these studies Sirtuin 1 (sirt1) was found to be protective in age-associated diseases. In apoE-/-mice, for example, the specific vascular Sirtuin 1 (Sirt1) deficiency, accelerated atherosclerosis (Gorenne, 2013) or cardiomyopathy (Planavila et al., 2012) , while activation of the Sirt1 provided atheroprotection in the same model (Miranda, 2015) . Mice overexpressing Sirt1 or specific activation of Sirt1 protected from metabolic disorders such as diabetes and liver steatosis and mice displayed healthy ageing (Herranz, 2010; Feige, 2008) . Gene inactivation of Foxo1, a transcription factor that regulates longevity genes and is modulated by Sirt1, in apoE-/-mice aggravated atherosclerosis and produced endothelial dysfunction (Qiang, 2012) .
On the other hand, ablation of the genes Cdkn2a/Cdkn2b (whose expression increases with age (Krishnamurthy, 2004) ) encoded by the Ink4/Arf locus promoted atherosclerosis in apoE-/-and Ldlr-/-mice (Gonzalez-Navarro, 2010; Kuo et al., 2011) . Consistently, overexpression of the Cdkn2a/Cdkn2b genes restored insulin-signalling and sensitivity associated with ageing (Gonzalez-Navarro, 2013) and diminished hepatic steatosis and IR in 1 year-aged Irs2+/− mice (Vinue, 2015) . Therefore, these mouse studies indicate a protective role of Cdkn2a/Cdkn2b genes in metabolic age-associated diseases. Telomere attrition, a process linked to ageing, restrained proliferation of leukocytes and atheroma progression in apoE-/-mice (Poch, 2004) . The study of mouse models with metabolic deficiencies either in lipid metabolism (in apoE, LDLr, apoB), in insulin-signalling (GH/insulin/IGF1-signalling) and altered mitochondrial dysfunction in combination or not with other agerelated processes (such as premature senescence, decreased or absence of Sirtuins) have provided many mechanistic insight about the ageing process and age-related chronic diseases. Most commonly used mouse models of metabolic derangements are listed in Table 5 .
Sleep and ageing
Ageing is characterized by impairments in physiological functions, reduced ability to react adaptively to environmental stimuli and increased susceptibility to disease (Troen, 2003; Vanhooren and Libert, 2013) , therefore it is not surprising that it brings with it alterations in sleep physiology. The percentage of global elderly population will increase in the next three decades and it has been reported that over 40% of people over 65, suffer from sleep disturbances (Foley et al., 2004) . Normal ageing is accompanied by changes in the sleep quality, its duration and architecture. Specifically, a decrease in the proportion of the deeper, more restorative, slow-wave sleep (SWS) and rapid eye movement (REM) sleep in the healthy elderly has been suggested. Furthermore, sleep latency and sleep fragmentation (waking up during the night) increments with age, leading to an increase of risk of developing physical and psychiatric illnesses. Indeed, sleep disturbance can induce depression (Jaussent et al., 2011; Tranah et al., 2010; Paudel et al., 2008) and increase the risk of neurodegeneration (Singletary and Naidoo, 2011) and mortality (Cappuccio et al., 2010) in the elderly population. Therefore, a crucial issue is to understand which risk factors can lead to sleep disturbances. To gain a better insight into this relevant question many mouse models have been developed to study the biology of ageing and neurodegeneration in association with sleep disturbances.
Experimental evidence suggests that sleep deprivation and disturbances in circadian rhythms may promote oxidative stress and play a role in the occurrence of hypertension, type 2 diabetes and neurodegenerative disorders. Most experimental evidence was obtained from different animal species, mainly rats and mice. Recent findings show that severe astrogliosis, oxidative damage and synaptic degeneration occur in Bmal1 mouse model; deletion in Bmal1 gene constitutes one of the core elements of the circadian transcriptional-translational feedback loop (TTFL). These data suggest that a decline in the circadian function, as seen in normal ageing, can exacerbate neurodegeneration via decreased BMAL1-mediated transcription (Musiek et al., 2015) .
Diabetes, hypertension and metabolic syndrome are well known co-morbidities of neurodegenerative diseases frequently found in the elderly. Although there are many different models of diabetes their sleep patterns have not been well studied and the related evidence is scarce. The ob/ob mouse shows a sleep disordered breathing that appears to exacerbate the already present pathology. The Zucker fatty rat is widely used in research to study type 2 diabetes and shows mutation in the leptin receptor (Phillips et al., 1996) leading to obesity, hyperphagia and hyperinsulinemia.
Recent evidence shows that Zucker fatty rats present a longer daily period of SWS suggesting that obesity and/or insulin resistance influences sleep patterns (Megirian et al., 1998) .
Disturbances of both sleep and circadian rhythms have long been associated with many neurological and psychiatric ageing-related diseases, including Alzheimer's disease. Alzheimer's diseasepatients show alterations in sleep-wake cycle activity. As described above, Alzheimer's diseaseis the most common agerelated neurodegenerative disorder. Recent research has provided evidence that chronic sleep restrictions can exacerbate A␤ pathology and can induce tau phosphorylation and synaptic injury in mouse models of Alzheimer's disease (Rothman et al., 2013; Di Meco et al., 2014) . Furthermore, recent studies in transgenic mice demonstrated that an increase of amyloid deposition and tau intracellular aggregation may impair sleep patterns, and consequently promote amyloid plaque formation. Abnormalities in the normal sleep architecture consists of phase delay (Duncan et al., 2012) , altered nocturnal activity level (Sterniczuk et al., 2010a (Sterniczuk et al., , 2010b and changes in non-REM sleep (Jyoti et al., 2010) . Thus, Alzheimer's diseasemouse models show sleep disturbances which are also present in AD patients.
In addition to Alzheimer's disease, Parkinson's Disease is a progressive disease of the nervous system marked by tremors, Fig. 1 . A summary figure highlighting the effects of ageing on different disease areas. Also included are similarities or differences between human disease and current mouse models where appropriate. (Loffredo et al., 2013; Barrientos et al., 2015; Matt and Johnson, 2016; Ziebell et al., 2016; Ojo et al., 2015; Lynch, 2015; Salminen et al., 2011; Jiang and muscular rigidity, slow and imprecise movements. Parkinson's Disease patients experience a severe impairment in normal sleep activity characterized by insomnia, excessive daytime sleepiness, increase number of nocturnal awakenings and REM-sleep behaviour disorder (Schrempf et al., 2014) . Several findings, using a dopamine-transporter KO mouse demonstrated a suppression of normal REM sleep (Lima et al., 2008; Dzirasa et al., 2006) although motor functions were not affected by the diminished dopaminergic tone. Furthermore, other evidence suggests that dopaminergic neurons of the ventral mesencephalic tegmentum may be important for REM sleep (Maloney et al., 2002) . In addition, it has been demonstrated using rat model that blockage of dopaminergic D(2) receptors produced decrease of REM but not of the slow wave sleep after REM sleep deprivation (Lima et al., 2008) . Thanks to recent studies carried out in rodent animal models, it can be suggested that PD and sleep may be intertwined, either as predictors or consequences of dopaminergic neurodegeneration.
Neurodegenerative and metabolic disorders associated with ageing lead to sleep disturbances in humans. The opportunity to reproduce age-related disorders with mutations and complex genome manipulation, give the possibility to further investigate the potential mechanisms that are responsible for sleep disturbances in elderly patients. The importance of investigating multimorbidities in mouse models is demonstrated by the observation that disrupted circadian rhythms can result in osteoarthritis (Gossan et al., 2013) . Thus, it is entirely feasible that a disease such as Alzheimer's disease can cascade through a disrupted circadian rhythm to promote susceptibility to other type of diseases such as osteoarthritis with the overarching age-related changes strongly contributing.
Looking to the future
Mouse studies continue to deliver insight into disease through a variety of physiological systems, and with the pressure of an ageing society it is certain that we will face an increased use of mice in ageing studies in the near future. The influence of ageing in the development of selected disease is summarized in Fig. 1 , including areas where there are differences between current models and patients. Ageing mouse studies, however present us with several problems, primarily cost and time. Ageing mice is expensive and time consuming, and results in difficulties in obtaining sufficient funding. It is therefore important to critically assess models on a continuous basis to determine their utility for clinically-relevant studies and determine whether new models are needed and/or deeper phenotypic information on existing models is required. This is particularly relevant as we learn more about co-morbidities associated with individual diseases. Furthermore, to study an ageing phenotype within the confines of a standard three year project grant would mean ideally having ageing mice already available when the grant starts, which is rarely feasible. There is therefore a need for flexibility in funding streams and funding proportionate to the increased costs of ageing mice. However, as funding is always highly competitive, we must also explore mechanisms for cost saving. One potential for cutting costs, and allowing the immediate availability of aged animals, is to have a centralised access to ageing mice, which may include the most common strains and models of age-relevant conditions. Building on the theme of centralisation, many studies are focused on a single phenotype and yet we often observe comorbidities in the aged (Fabbri et al., 2015) , and therefore providing central facilities with a wide range pf phenotypic capabilities will allow a deeper analysis of phenotypes in a single model. The range of phenotypes associated with ageing is emphasised by the limited examples of models highlighted above. Ideally, a range of phenotypic assays would be applied to aged mouse models to provide a centralised comprehensive phenotypic analysis of mutants under different test conditions, similar to the Mouse Clinic model (Ayadi et al., 2012) or Intervention Testing Programme (Miller et al., 2007; Warner et al., 2000) . Developing such resources will be a challenge but infrastructures supporting mouse research (Consortium, 2015) provide a stepping stone and centralised expertise and services would no doubt facilitate the study of ageing and age-related disease. Furthermore, as highlighted here, more work is needed to understand the relevance and utility of the various models to study age-related diseases. This effort will continue within the recently formed MouseAGE COST action to provide this information in an easily accessible form with consensus recommendations from experts in the various fields.
